Clinical Study Results
Research Sponsor: AstraZeneca AB
Drug Studied: Osimertinib
Study Purpose: This study was done to learn how well
osimertinib works in participants with
advanced non-small cell lung cancer
Protocol Number: D5160C00022
Thank you
Thank you for taking part in the clinical study for the study drug osimertinib, also called
AZD9291.
You and all of the participants helped researchers learn more about osimertinib to help people
with a type of lung cancer called advanced non-small cell lung cancer, also called “advanced
NSCLC”.
AstraZeneca AB sponsored this study and believes it is important to share the results of the
study with you and the public. An independent non-profit organization called CISCRP helped
prepare this summary of the study results for you. We hope it helps you understand and feel
proud of your important role in medical research.
If you participated in the study and have questions about the results, please speak with the
study doctor or staff at your study site.
1